Kelly Underhill, MD
Radiation Oncology · Lebanon, NHNPI 1447275870
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $427 and has fallen 96.2% since, to $16 in 2025.
Across 62 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$226
- Johnson & Johnson$153
- Merck$127
- Siemens Medical Solutions USA, Inc.$104
- Amgen$65
- Medtronic$34
- plus $420 from 22 others
What the payments were for
- Food & beverage$1,128100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 14 | $226 |
| Johnson & Johnson(2 entities) | 9 | $153 |
| Merck | 7 | $127 |
| Siemens Medical Solutions USA, Inc. | 2 | $104 |
| Amgen | 4 | $65 |
| Medtronic | 1 | $34 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $34 |
| Stemline Therapeutics Inc. | 2 | $33 |
| Genmab U.S., Inc. | 2 | $32 |
| Acrotech Biopharma Inc. | 1 | $24 |
| Varian Medical Systems, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Blueprint Medicines Corporation | 1 | $21 |
| Genentech USA, Inc. | 1 | $19 |
| Bristol Myers Squibb | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| AbbVie | 1 | $18 |
| Pfizer | 1 | $17 |
| Gilead | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| GSK | 1 | $14 |
| Clovis Oncology, Inc. | 1 | $14 |
| Spectrum Pharmaceuticals Inc. | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $12 |
| Seagen Inc. | 1 | $12 |
How this compares
$1,128 in reported general payments places this provider in the 85th percentile of 35 radiation oncology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 13 | $421 |
| Tamsulosin Hcl | 31 | $267 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Lebanon
- James YuLebanon$112K
- Evangelia KatsoulakisLebanon$16K
- Nirav KapadiaLebanon$485
- Gregory RussoLebanon$383
- Bassem ZakiLebanon$360
- Katie LichterLebanon$142
- Thomas DelaneyLebanon$102
- Liza StaplefordLebanon$89
- Charles ThomasLebanon$22
- Lesley JarvisLebanon$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.